The frantic pace of inversion deals that once saved U.S. corporations millions of dollars in taxes while heaping riches on the law firms that helped structure them are slowing to a crawl.
Since the U.S. Department of the Treasury issued a notice on Sept. 22 that tightened regulations for inversions, at least three large pending deals have fallen apart: Abbvie’s $54 billion merger with U.K.-based Shire on Oct. 20; Auxilium Pharmaceuticals Inc.’s $345 million merger with Vancouver-based biotechnology company QLT Inc. on Oct. 8.; and Salix Pharmaceuticals Ltd.’s $2.7 billion acquisition of Italian drugmaker for gastrointestinal diseases Cosmo Pharmaceuticals S.p.A on Oct. 3.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]